Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sexually Transmitted Infection (STI) Clear all
Completed Phase 1 Interventional

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

NCT00000649
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

NCT03205917
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

NCT00002217
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 21, 2026, 6:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preventing Health Damaging Behaviors in Male and Female Army Recruits

NCT01234103
View directory record Official record
Conditions
Sexually Transmitted Infection (STI) Prevention, Unintended Pregnancy Prevention, Sexual Risk Reduction, Alcohol and Other Substance Use Prevention, Intimate Partner Violence Prevention
Interventions
Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

NCT03350672
View directory record Official record
Conditions
Hiv
Interventions
FTC/TAF
Drug
Lead sponsor
Philadelphia Fight
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NCT00002137
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 6:34 PM EDT
Completed No phase listed Observational

Outcomes of Anti-HIV Therapy During Early HIV Infection

NCT00001093
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 21, 2026, 6:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

NCT00001210
View directory record Official record
Conditions
HIV Infections, Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
View directory record Official record
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

NCT00000669
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Implementation Science to Increase Pre-Exposure Prophylaxis Uptake Among African American Women

NCT05139069
View directory record Official record
Conditions
HIV Infections, Domestic Violence
Interventions
Trauma-Informed Toolkit
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 21, 2026, 6:34 PM EDT
Enrolling by invitation No phase listed Observational

Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

NCT07461350
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 6:34 PM EDT
Not listed Phase 2 Interventional

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

NCT04560569
View directory record Official record
Conditions
HIV/AIDS
Interventions
Albuvirtide, 3BNC117 Antibody
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Canoga Park, California • San Francisco, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 21, 2026, 6:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

NCT01519141
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 3 Interventional

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

NCT00002109
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
48
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 6:34 PM EDT
Completed No phase listed Observational Results available

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional

HPV Self-Test Intervention in Ohio Appalachia

NCT02460237
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Disease Screening, Educational Intervention, Informational Intervention, Laboratory Biomarker Analysis, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 21, 2026, 6:34 PM EDT
Withdrawn No phase listed Observational

Prospective Study of Lymphoproliferative Diseases

NCT01704742
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions
Not listed
Lead sponsor
West Virginia University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

NCT00002186
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer, Acyclovir
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
NNRTI, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 21, 2026, 6:34 PM EDT